Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (February 2025)

54 slides from Corbus Pharmaceuticals's investor presentation, Feb 14, 2025

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation February 14, 2025 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, prod

  3. Slide 3: A Diversified Pipeline with Differentiated Clinical Risk Profiles

    Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Multiple Cohorts Expanding Corbus (US + Europe) Dose optimization in mUC, HNSCC& cervic

  4. Slide 4: CRB-701 Next Generation Nectin-4 Targeting ADC

    CRB-701 Next Generation Nectin-4 Targeting ADC

  5. Slide 5: Designing a Nectin-4 ADC Intended to Address PADCEV Unmet Needs

    Extend ADC half-life  Reduce dosing frequency Convenience Lower DAR + longer half-life  Dose higher than PADCEV® Efficacy Nectin-4 targeting ADC for treatment of solid tumors Safety Designing a Nectin-4 ADC Intended to Address PADCEV® Unmet Needs

  6. Slide 6: CRB-701: Next Generation Nectin-4 Targeting ADC

    CRB-701: Next Generation Nectin-4 Targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity Source(s): Modified image from Corbus data on file; Corbus data on file Novel nectin-4 Antibody ADCC + CDC functionality Glutamine F

  7. Slide 7: CRB-701: Best-in-Class Dosing Regimen

    CRB-701: Best-in-Class Dosing Regimen Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2023 CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility

  8. Slide 8: Phase 1 Dose Escalation Studies: Trial Design

    Phase 1 Dose Escalation Studies: Trial Design KEY ELIGIBILITY Age ≥ 18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function Stable ongoing comorbidities No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design with

  9. Slide 9: Phase 1 Dose Escalation Studies: Key Characteristics

    Phase 1 Dose Escalation Studies: Key Characteristics Median age (range) 55 (35, 76) 62 (34, 90) Sex (M/F) 29.7%, 70.3% 42.1%, 57.9% ECOG PS 0,1, missing 8.1%, 89.2%, 2.7% 23.7%, 71.1%, 5.3%, 0% Weight in kg mean (range) 59.01 (36.0, 84.9) 67.9 (32.1 111.8) Prior therapies median (range) 4 (0,10) 3 (

  10. Slide 10: Phase 1 Dose Escalation Studies: TEAEs

    Phase 1 Dose Escalation Studies: TEAEs Summary of TEAEs ≥20% (n=37) Summary of TEAEs ≥ 15 % (n=38) Portion of patients (%) Portion of patients (%) Sources: CSPC data: ASCO 2024 Corbus data: ASCO GU 2025

  11. Slide 11: Phase 1 Dose Escalation Studies: Few Skin and PN Events

    AE Grade N of 37 Notes Skin rash 1 x Grade 1 1 x Grade 2 1 x Grade 3 3 (8.1%) All resolved PN 1 x Grade 1 1 (2.7%) Resolved AE Grade N of 38 Notes Skin rash 4 x Grade 1 4 (10.5%) Other skin AEs Pruritis (itchy skin) 5 x Grade 1 5 (13.2%) Blister 1 x Grade 1 1 x Grade 2 2 (5.3%) Rash maculopapular 1

  12. Slide 12: Phase 1 Dose Escalation Studies: Low Rates of Dose Modifications

    Phase 1 Dose Escalation Studies: Low Rates of Dose Modifications Sources: Padcev data: NDA/BLA Multi-disciplinary Review and Evaluation – BLA 761137 PADCEV™ (enfortumab vedotin-ievx). Derived from Table 45 CSPC data: ASCO 2024 Corbus data: ASCO GU 2025 Dose Modification 1.25 mg/kg (n=300) 1.8-4.5 mg

  13. Slide 13: Phase 1 Dose Escalation Studies: Ocular Toxicity is Manageable

    CSPC Dose Optimization PK Cohorts Corbus Dose Optimization Project Optimus Dose Cohorts Phase 1 Dose Escalation Studies: Ocular Toxicity is Manageable Sources: CSPC data: ASCO 2024, Corbus data: ASCO GU 2025 1.8 mg/kg N=3 2.7 mg/kg N=10 3.6 mg/kg N=14 4.5 mg/kg N=3 1.8 mg/kg N=13 2.7 mg/kg N=11 3.6

  14. Slide 14: Favorable Emerging Combined Safety Profile vs. Nectin-4-MMAE Peers

    Favorable Emerging Combined Safety Profile vs. Nectin-4-MMAE Peers Sources: 1.JCO, 2020 Apr 1; 38(10): 1041–1049, Rosenberg et al 2. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV® (enfortumab vedotin) 3. Torras, O. Reig, et al. "652P BT8009 monotherapy in enfortumab vedotin (EV)-

  15. Slide 15: PK Data: Lower levels of MMAE for CRB-701 vs. PADCEV

    Company 21-day PK Comparison % ADC % Free MMAE Cmax AUC0-21d Cmax AUC0-21d PADCEV™ 1.24 mg/kg Q1W x 3 PADCEV™ Benchmark 100% 100% 100% 100% 2.7 mg/kg Q3W Matched for MMAE dose (DAR) 191% 251% 67% 56% 3.6 mg/kg Q3W 2.9-fold PADCEV™ ADC Dose 289% 405% 73% 73% 2.7 mg/kg Q3W Matched for MMAE dose (DAR)

  16. Slide 16: Phase 1 Dose Escalation Studies: Waterfall Plots

    Phase 1 Dose Escalation Studies: Waterfall Plots *confirmed response Across all patients in waterfall plot ORR DCR Corbus (n=26) 27% 77% CSPC (n=25) 28% 68% SD* HNSCC patent with a clinical PR coded to SD because the target lesion was occluded by invasive aspergillosis. PD* Cervical patient with tum

  17. Slide 17: Phase 1 Dose Escalation Studies: Swimmer Plots

    Phase 1 Dose Escalation Studies: Swimmer Plots Sources: CSPC data: ASCO 2024, Corbus data: ASCO GU 2025, N=37, Data were unavailable for one patient (Infusion only no duration data). Best overall response is indicated at the end of each bar. Bold text indicates confirmed responses, all other respons

  18. Slide 18: Phase 1 Dose Escalation Studies: mUC

    Phase 1 Dose Escalation Studies: mUC Sources CSPC data: ASCO 2024: Patients dosed with >1.2mg/Kg, Corbus data: ASCO GU 2025 *Patient admitted with SAE of unrelated dyspnoea and presumptive PD in the liver. Patient excluded from Waterfall plot due to disease progression prior to first tumor assessmen

  19. Slide 19: Phase 1 Dose Escalation Studies: Cervical cancer

    Phase 1 Dose Escalation Studies: Cervical cancer Sources: CSPC data: ASCO 2024: for patients dosed >1.2mg/Kg Corbus data: ASCO GU 2025 ORR: 43% (3 out of 7) DCR: 86% (6 out of 7) ORR: 1 out of 2 DCR: 1 out of 2 Response Dose (mg/kg) Nectin-4 H score Notes PD (-61.42%) 1.8 205 Ongoing treatment with

  20. Slide 20: Corbus Phase 1 Dose Escalation Study: HNSCC Emerges As New Target

    Corbus Phase 1 Dose Escalation Study: HNSCC Emerges As New Target Dose mg/kg 1.8 2.7 1.8 3.6 3.6 1.8 Nectin-4 H score 210 250 165 280 25 165 SD* HNSCC patent with a clinical PR coded to SD because the target lesion was occluded by invasive aspergillosis. CR, complete response; HNSCC, head and neck s

  21. Slide 21: HNSCC Case Study: Clinical Improvement in Patient with Resistant Disease

    Prior therapies Carboplatin+docetaxel+5FU 3 weeks (PD) then Cisplatin 4 weeks (PD) then pembrolizumab 6 weeks (PD) then experimental bispecific antibody duration of Rx unknown (PD) HNSCC Case Study: Clinical Improvement in Patient with Resistant Disease Baseline tumor assessment 09/19/2024 6-week fo

  22. Slide 22: Combined CSPC + Corbus Dataset for mUC, Cervical and HNSCC

    What Does a Combined CSPC + Corbus Dataset Look Like for mUC + Cervical + HNSCC? Sources CSPC data: ASCO 2024 Corbus data: ASCO GU 2025 3.6 1.8 3.6 3.6 1.8 3.6 1.8 0.6 3.6 0.6 2.7 0.2 3.6 0,6 1.8 4.5 2.7 2.6 1.8 3.6 2.7 3.6 3.6 3.6 3.6 3.6 1.8 1.2 1.8 1.8 2 7 80 30 205 0 295 110 210 68 265 25 105 80

  23. Slide 23: CRB-701 Corbus Study Design

    CRB-701 Corbus Study Design Dose escalation Project Optimus (Dose optimization) Dose expansion at RP2D Randomized to 2.7 or 3.6 mg/kg monotherapy in: HNSCC Cervical mUC mUC Non-UC tumors: A B C Basket of nectin-4 positive tumors Ongoing 1.8 mg/kg 2.7 mg/kg 3.6 mg/kg 4.5 mg/kg Randomized to 2 doses o

  24. Slide 24: Indications of Interest

    Indications of Interest: Source: SEER Bladder Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Chu et al., 2022; Hoffman-Censits et al., 2022. SEER Cervical Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Mizuho Analyst Report; Corbus Corporate Deck. SEER Oral Cavity &

  25. Slide 25: CRB-701: Summary of Latest Data

    One dose in 21-day cycle (vs PADCEV™ Q1Wx3) Fewer reductions/interruptions/discontinuations vs PADCEV ® Convenience Promising emerging efficacy in HNSCC Responses in both cervical and PADCEV-naïve mUC cancer Efficacy Markedly fewer skin and PN AEs vs PADCEV® Prophylaxis reduces ocular tox from 66% 

  26. Slide 26: CRB-913 Oral CB1 inverse agonist for obesity

    CRB-913 Oral cannabinoid Type-1 inverse agonist for superior incretin therapy in obesity

  27. Slide 27: CB1 is a Well-Understood Receptor in Metabolism

    Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. CB1 is a Well-Understood Receptor in Metabolism >9K papers in PubMed on CB1 and metabolism

  28. Slide 28: Next-Generation CB1 Inverse Agonists are Peripherally Restricted

    Monlunabant CRB-913 Next-Generation CB1 Inverse Agonists are Peripherally Restricted Rimonabant Otenabant Ibipinabant Taranabant Source(s): Cinar et al 2020 First-generation (2000-2007) Next-generation (2020 onwards) Designed to target the brain with high BBB penetration  FDA rejection due to safet

  29. Slide 29: Clinical Efficacy of Monlunabant vs Rimonabant: What Do We Know?

    Clinical Efficacy of Monlunabant vs Rimonabant: What Do We Know? * Sourcs: RIO North America (Pi Snuyer et al 2006) ** Novo PR Sept 2024 *** Crater et al 2023 N =345* N =346* N =60** N = 20*** Placebo-adjusted weight loss cross-trial comparison Change in weights (kg) Weeks

  30. Slide 30: CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist

    CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist Design Goals Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

  31. Slide 31: CRB-913 is the Outcome of a Multi-year Medicinal Chemistry Campaign

    Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral Same backbone as Inversago compounds (MRI/INV family) CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK di

  32. Slide 32: CRB-913: Higher Degree of Peripheral Restriction

    Source(s): *Morningstar et al Obesity Week poster 2024 CRB-913: Higher Degree of Peripheral Restriction Than Monlunabant or Rimonabant Cmax Brain concentration (ng/g) Dose CRB-913 Monlunabant Rimonabant 10 mg/kg 22 344 561 1:15 1:26 1:1.6 Cmax = 561 Cmax = 344 Cmax = 22 AUC = 3855 AUC = 265 1:15 Bra

  33. Slide 33: CRB-913: Potential Clinical Usage and Supportive Pre-clinical Data

    1. Incretin analog therapy for insensitive/intolerant/high-risk patients 2. Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability 3. “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy CRB-913: Potential Clini

  34. Slide 34: CRB-913: Dose Response Weight Loss Across Wide Range in DIO Mice

    Source(s): Morningstar et al 2024 Obesity Week poster CRB-913: Dose Response Weight Loss Across Wide Range in DIO Mice Allometric scaling to humans: 30 mg/day to >450 mg/day Top weight loss observed: 38% for 80 mg/kg/day QD on day 28 Weight loss (%) by day 19 in DIO mice

  35. Slide 35: CRB-913: Enhanced Combo Effect with Semaglutide or Tirzepatide

    CRB-913: Enhanced Combo Effect with Semaglutide or Tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weigh

  36. Slide 36: CRB-913: Induction/Maintenance with Semaglutide

    CRB-913: Induction/Maintenance with Semaglutide Source(s): Obesity Week poster 2024 “Switch” ↓ Vehicle Sema  vehicle Sema  Sema Sema  CRB-913

  37. Slide 37: Weight Loss from CRB-913 Driven by More Fat Loss than Semaglutide

    Weight Loss from CRB-913 Driven by More Fat Loss than Semaglutide Sources: Obesity Week poster 2024 SemaSema SemaCRB-913 At day 41 (end of study period) Sema  Sema Sema  CRB-913 Difference Weight loss (%) -13.6 -17.1 ↑25% Fat change from baseline -3.65% -8.65% ↑2.3x Vehicle

  38. Slide 38: Clinical Development Pathway to Determination of Dose Response Curve

    Clinical Development Pathway to Determination of Dose Response Curve H1 2025 H2 ‘25 – H1 ‘26 H2 ’26 – H1 ‘27 2022-2023 2023-2024 2025-2026 (?) 25 mg/day 28-day (n=37) 10, 20 and 50 mg/day 16 wks (n=240) Additional dose response study (n=600) Ph1a SAD  MAD Ph1b Dose response study Phase 2

  39. Slide 39: CRB-601 Potential best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  40. Slide 40: CRB-601 has the Potential to Enhance Checkpoint Inhibition

    CRB-601 has the Potential to Enhance Checkpoint Inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  41. Slide 41: TGFb Predicts Poor Clinical Outcomes in a Subset of Cancer Patients

    TGFβ Predicts Poor Clinical Outcomes in a Subset of Cancer Patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C

  42. Slide 42: Targeting the Integrin avb8 Represents a Novel Approach to Regulating TGFb

    Targeting the Integrin ⍺vβ8 Represents a Novel Approach to Regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  43. Slide 43: CRB-601 is Targeting Latent-TGFb by Blocking the Integrin avb8

    CRB-601 is Targeting Latent -TGFβ by Blocking the Integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

  44. Slide 44: mAbs Targeting TGFb Activation in the Clinic

    mAbs Targeting TGFβ Activation in the Clinic Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage Phase 1 Phase 1/2 –study completed December 2024 Phase 1 Phase 2 HCC (read-out in 2025)

  45. Slide 45: CRB-601 Enhances Anti-PD-1 Therapy in Murine Tumor Models

    CRB-601 Enhances Anti-PD-1 Therapy in Checkpoint Inhibition Sensitive and Resistant Murine Tumor Models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB

  46. Slide 46: Blockade of avb8 with Anti-PD-1 Increased TIL Populations in EMT6 Tumors

    Blockade of ⍺vβ8 in Combination with Anti-PD-1 Increased TIL Populations in Immune Excluded EMT6 Tumors Source(s): Corbus data on file **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days

  47. Slide 47: CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors

    CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors Source(s): Corbus data on file

  48. Slide 48: Applying a Proprietary Algorithm to Define the Clinical Focus for CRB-601

    Applying a Proprietary Algorithm to Define the Clinical Focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):

  49. Slide 49: Patient Selection Strategies will Enhance the Probability of Success

    Patient Selection Strategies will Enhance the Probability of Success Source(s): Corbus proprietary analysis: Log2 fold change of ⍺vβ8 expression as a ratio to normal tissue Prioritization of indications with differential gene expression vs. normal tissues will emphasize focus on the tumor potential

  50. Slide 50: Leadership Upcoming Catalysts Financials

    Leadership Upcoming Catalysts Financials

  51. Slide 51: Management Team

    Management Team Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Christina Bertsch Head of Human Resources Accomplished senior human resource executive

  52. Slide 52: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience;

  53. Slide 53: Corporate Milestones

    Corporate Milestones Dose first patient in Ph1 SAD/MAD: Q1-2025 Start Ph1B study: Q4-2025 Complete Ph1 dose escalation: Q4-2025 Present Western Ph1 dose escalation data: Q-12025 Complete dosing under Project Optimus and establish RP2D: Q4-2025 CRB-701 CRB-913 CRB-601

  54. Slide 54: Investment Summary

    Investment Summary $159M Cash, cash equivalents and investments as of September 30, 2024. Approximately 12.2M Common Shares Outstanding (~13.2M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb fo

Corbus Pharmaceuticals Holdings — Investor Presentation (February 2025) on 6ix